Breaking News Instant updates and real-time market news.

MEC

Mayville Engineering

$7.08 /

-0.58 (-7.57%)

17:03
02/26/20
02/26
17:03
02/26/20
17:03

Mayville Engineering reports Q4 EPS (8c), consensus (16c)

Reports Q4 revenue $102.33M, consensus $100.04M. "2019 was an important year for our Company during which we reached numerous important milestones including completing our IPO and the integration of DMP," explained Robert D. Kamphuis, Chairman, President and CEO. "Our full year results highlight the overall strength of our business, which more recently has been impacted by the sudden shifts in demand that we started to experience late in the third quarter. We believe much of the dramatic downshift in demand has slowed and we will continue to align our cost structure to market conditions. Going forward, we are reaffirming our 2020 outlook and remain focused on leveraging our agility to shift our capacities and pursue new customer opportunities."

  • 27

    Feb

MEC Mayville Engineering
$7.08 /

-0.58 (-7.57%)

10/29/19
Mayville Engineering reports Q3 EPS 49c, consensus 32c
06/14/19 William Blair
Mayville story unchanged despite share weakness, says William Blair
06/03/19 William Blair
Mayville Engineering initiated with an Outperform at William Blair
06/03/19
Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Periodicals
GlaxoSmithKline drug pipeline should drive stock higher, Barron's says » 09:47
06/06/20
06/06
09:47
06/06/20
09:47
GSK

GlaxoSmithKline

$41.69 /

+0.04 (+0.10%)

Pharmaceuticals are one…

Pharmaceuticals are one of the defensive stocks in the current crisis, but it is too early to quantify the magnitude of a coronavirus benefit, Rupert Steiner writes in this week's edition of Barron's. Nonetheless, GlaxoSmithKline is worth paying attention to for unrelated developments that aren't yet factored into its value, the author notes, highlighting its trial of Cabotegravir, a regular injection to prevent HIV infection, that has been stopped three years early because of its success. Glaxo is also undergoing a restructuring, spinning off the consumer-health division that makes Advil and Panadol, and has a strong pipeline of potential blockbusters on the way, he adds. Reference Link

ShowHide Related Items >><<
GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

Periodicals
Antibody drugs could help curb pandemic, Barron's says » 09:40
06/06/20
06/06
09:40
06/06/20
09:40
GSK

GlaxoSmithKline

$41.69 /

+0.04 (+0.10%)

, VIR

Vir Biotechnology

$33.16 /

-1.06 (-3.10%)

, LLY

Eli Lilly

$149.21 /

-1.44 (-0.96%)

, REGN

Regeneron

$597.27 /

-0.94 (-0.16%)

, NVAX

Novavax

$46.22 /

+1.54 (+3.45%)

, MRNA

Moderna

$58.16 /

-2.44 (-4.03%)

Chasing COVID-19 vaccine…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

06/05/20 Piper Sandler
Nektar sees 'encouraging trends' in early lupus trial, says Piper Sandler
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
REGN Regeneron
$597.27 /

-0.94 (-0.16%)

06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Barclays
Regeneron price target raised to $615 from $530 at Barclays
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
NVAX Novavax
$46.22 /

+1.54 (+3.45%)

06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
MRNA Moderna
$58.16 /

-2.44 (-4.03%)

06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

Periodicals
Zoom stock reaction could suggest trouble for much of tech, Barron's says » 09:33
06/06/20
06/06
09:33
06/06/20
09:33
ZM

Zoom Video

$207.60 /

-2.64 (-1.26%)

Zoom Video had one of the…

Zoom Video had one of the best earnings reports in the history of American business, sending the shares up 7.6% on Wednesday, Eric Savitz writes in this week's edition of Barron's. But the stock gave it all back plus more by the end of the week, which has to be a little worrisome for Zoom bulls, the author notes. The response suggests one has reached the upper limits of the remarkable rally in work-from-home stocks, he adds. Reference Link

ShowHide Related Items >><<
ZM Zoom Video
$207.60 /

-2.64 (-1.26%)

ZM Zoom Video
$207.60 /

-2.64 (-1.26%)

06/05/20 JPMorgan
DocuSign price target raised to $150 from $90 at JPMorgan
06/05/20 DA Davidson
Slack Technologies price target raised to $32 from $29 at DA Davidson
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
06/03/20
Fly Intel: Top five analyst upgrades
ZM Zoom Video
$207.60 /

-2.64 (-1.26%)

ZM Zoom Video
$207.60 /

-2.64 (-1.26%)

ZM Zoom Video
$207.60 /

-2.64 (-1.26%)

ZM Zoom Video
$207.60 /

-2.64 (-1.26%)

Periodicals
MGM Growth Properties a safe Vegas dividend-yield play, Barron's says » 09:28
06/06/20
06/06
09:28
06/06/20
09:28
MGM

MGM Resorts

$21.71 /

+ (+0.00%)

, MGP

MGM Growth

$29.02 /

-0.085 (-0.29%)

As Las Vegas begins to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

MGM MGM Resorts
$21.71 /

+ (+0.00%)

MGM MGM Resorts
$21.71 /

+ (+0.00%)

05/21/20
Fly Intel: Top five analyst downgrades
05/21/20 Credit Suisse
MGM Resorts assumed with a Neutral at Credit Suisse
05/21/20 BofA
MGM Growth upgraded to Buy from Neutral at BofA
05/21/20 BofA
MGM Resorts downgraded to Underperform from Neutral at BofA
MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

05/28/20 JPMorgan
MGM Growth LLC conversation 'major catalyst' for shares, says JPMorgan
05/19/20 Baird
MGM Growth upgraded to Outperform at Baird
05/19/20 Baird
MGM Growth upgraded to Outperform from Neutral at Baird
MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

MGM MGM Resorts
$21.71 /

+ (+0.00%)

MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

MGM MGM Resorts
$21.71 /

+ (+0.00%)

MGM MGM Resorts
$21.71 /

+ (+0.00%)

MGM MGM Resorts
$21.71 /

+ (+0.00%)

Periodicals
Sysco, US Foods could benefit when dining out returns, Barron's says » 09:23
06/06/20
06/06
09:23
06/06/20
09:23
PFGC

Performance Food Group

$31.41 /

+3.135 (+11.09%)

, USFD

US Foods

$23.36 /

+2.245 (+10.63%)

, SYY

Sysco

$61.60 /

+3.02 (+5.16%)

Restaurant are gradually…

Restaurant are gradually reopening for dining service and a recovery could bake in recent gains for the three largest restaurant suppliers, namely Sysco (SYY), US Foods (USFD) and Performance Food Group (PFGC), Daren Fonda writes in this week's edition of Barron's. The stocks should rise as states allow restaurants to reopen dining rooms, and the economy gradually recovers, and even if many local restaurants never reopen, distributors could become more profitable by servicing fewer locations, gaining efficiency, and lifting operating margins, the author notes. Reference Link

ShowHide Related Items >><<
USFD US Foods
$23.36 /

+2.245 (+10.63%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

05/05/20 Guggenheim
Performance Food risk/reward compelling with 50% upside, says Guggenheim
04/23/20 BMO Capital
Performance Food downgraded to Market Perform from Outperform at BMO Capital
04/20/20 Credit Suisse
Performance Food Group reinstated with an Outperform at Credit Suisse
03/26/20 Jefferies
Performance Food Group upgraded to Buy from Hold at Jefferies
USFD US Foods
$23.36 /

+2.245 (+10.63%)

05/18/20 Guggenheim
US Foods price target lowered to $30 from $50 at Guggenheim
04/27/20 Credit Suisse
US Foods price target lowered to $27 from $47 at Credit Suisse
04/23/20 BMO Capital
US Foods downgraded to Market Perform from Outperform at BMO Capital
04/06/20 JPMorgan
US Foods price target lowered to $24 from $45 at JPMorgan
SYY Sysco
$61.60 /

+3.02 (+5.16%)

06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 Wells Fargo
Sysco upgraded to Overweight from Equal Weight at Wells Fargo
06/05/20 Wells Fargo
Sysco upgraded to Overweight from Equal Weight at Wells Fargo
06/01/20 Piper Sandler
Sysco upgraded to Overweight from Neutral at Piper Sandler
USFD US Foods
$23.36 /

+2.245 (+10.63%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

USFD US Foods
$23.36 /

+2.245 (+10.63%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

Periodicals
FMC stock 'the pick of the crop' among agribusinesses, Barron's says » 09:17
06/06/20
06/06
09:17
06/06/20
09:17
CTVA

Corteva

$30.69 /

+0.55 (+1.82%)

, FMC

FMC Corporation

$103.29 /

+3.59 (+3.60%)

The food business has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

CTVA Corteva
$30.69 /

+0.55 (+1.82%)

CTVA Corteva
$30.69 /

+0.55 (+1.82%)

06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
05/11/20 RBC Capital
Corteva price target raised to $31 from $27 at RBC Capital
05/11/20 BofA
Nutrien, Mosaic, Corteva, CF Industries cut to Underperform at BofA
05/11/20 BofA
Corteva downgraded to Underperform from Neutral at BofA
FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
05/07/20 KeyBanc
FMC Corporation price target raised to $108 from $93 at KeyBanc
05/07/20 Citi
FMC Corporation price target raised to $114 from $107 at Citi
04/06/20 SunTrust
FMC Corporation price target lowered to $106 from $125 at SunTrust
FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

CTVA Corteva
$30.69 /

+0.55 (+1.82%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

CTVA Corteva
$30.69 /

+0.55 (+1.82%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

CTVA Corteva
$30.69 /

+0.55 (+1.82%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

Periodicals
Gold-mining merger could add sparkle to new SSR, Barron's says » 09:10
06/06/20
06/06
09:10
06/06/20
09:10
ALIAF

Alacer Gold

$0.00 /

+ (+0.00%)

, SSRM

SSR Mining

$17.97 /

-0.34 (-1.86%)

Last month, SSR (SSRM)…

Last month, SSR (SSRM) and Alacer (ALIAF), each with roughly $2B in market value, announced plans to combine in a no-premium merger of equals, with Rod Antal, Alacer's chief executive, becoming CEO of the combined company, which will take SSR's name, Nicholas Jasinski writes in this week's edition of Barron's. SSR and Alacer have complementary strengths, and the combined company's increased scale is expected to provide a bevy of financial benefits, the author notes, adding that as a result, the market is likely to reward the new SSR with a higher valuation than either company could have achieved on its own. Reference Link

ShowHide Related Items >><<
SSRM SSR Mining
$17.97 /

-0.34 (-1.86%)

ALIAF Alacer Gold
$0.00 /

+ (+0.00%)

ALIAF Alacer Gold
$0.00 /

+ (+0.00%)

05/05/20 RBC Capital
Alacer Gold price target raised to C$8 from C$7 at RBC Capital
05/01/20 CIBC
Alacer Gold price target raised to C$9 from C$8 at CIBC
04/01/20 BMO Capital
Alacer Gold upgraded to Outperform from Market Perform at BMO Capital
02/11/20 Stifel
Alacer Gold upgraded to Buy from Hold at Stifel
SSRM SSR Mining
$17.97 /

-0.34 (-1.86%)

05/14/20 RBC Capital
SSR Mining price target raised to $21 from $18 at RBC Capital
02/24/20 Canaccord
SSR Mining downgraded to Hold from Buy at Canaccord
02/21/20 Scotiabank
SSR Mining downgraded to Sector Perform from Outperform at Scotiabank
11/13/19 B. Riley FBR
B. Riley FBR upgrades SSR Mining to Buy, boosts target to $23
SSRM SSR Mining
$17.97 /

-0.34 (-1.86%)

SSRM SSR Mining
$17.97 /

-0.34 (-1.86%)

ALIAF Alacer Gold
$0.00 /

+ (+0.00%)

SSRM SSR Mining
$17.97 /

-0.34 (-1.86%)

Periodicals
Twitter battle with Trump may be good for stock, Barron's says » 09:04
06/06/20
06/06
09:04
06/06/20
09:04
TWTR

Twitter

$34.86 /

+1.13 (+3.35%)

Last month, Twitter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$34.86 /

+1.13 (+3.35%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

05/29/20 Baird
Twitter, Facebook pullbacks would likely be buying opportunities, says Baird
05/29/20 JPMorgan
Trump order may put 'overhang' on big tech in coming months, says JPMorgan
05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
TWTR Twitter
$34.86 /

+1.13 (+3.35%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

On The Fly
Week in Review: How Trump's policies moved stocks » 07:19
06/06/20
06/06
07:19
06/06/20
07:19
AZN

AstraZeneca

$53.87 /

+ (+0.00%)

, JNJ

Johnson & Johnson

$147.27 /

+0.61 (+0.42%)

, MRK

Merck

$82.26 /

+0.71 (+0.87%)

, MRNA

Moderna

$58.16 /

-2.44 (-4.03%)

, PFE

Pfizer

$35.97 /

-0.035 (-0.10%)

, INO

Inovio

$11.96 /

+0.09 (+0.76%)

, NVAX

Novavax

$46.22 /

+1.54 (+3.45%)

, AIRYY

Air China

$0.00 /

+ (+0.00%)

, CEA

China Eastern Airlines

$20.34 /

+1.54 (+8.19%)

, ZNH

China Southern Airlines

$25.21 /

+2.57 (+11.35%)

, AAL

American Airlines

$18.59 /

+1.855 (+11.08%)

, DAL

Delta Air Lines

$34.15 /

+1.77 (+5.47%)

, UAL

United Airlines

$42.41 /

+3.33 (+8.52%)

, SNAP

Snap

$20.32 /

+1.065 (+5.53%)

, FB

Facebook

$230.64 /

+4.38 (+1.94%)

, GOOG

Alphabet

$1,436.75 /

+24.625 (+1.74%)

, GOOGL

Alphabet Class A

$1,440.74 /

+26.62 (+1.88%)

, AAPL

Apple

$331.38 /

+9.09 (+2.82%)

, AMZN

Amazon.com

$2,481.08 /

+20.67 (+0.84%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
ZNH China Southern Airlines
$25.21 /

+2.57 (+11.35%)

UAL United Airlines
$42.41 /

+3.33 (+8.52%)

SNAP Snap
$20.32 /

+1.065 (+5.53%)

PFE Pfizer
$35.97 /

-0.035 (-0.10%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MRK Merck
$82.26 /

+0.71 (+0.87%)

JNJ Johnson & Johnson
$147.27 /

+0.61 (+0.42%)

INO Inovio
$11.96 /

+0.09 (+0.76%)

GOOGL Alphabet Class A
$1,440.74 /

+26.62 (+1.88%)

GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

DAL Delta Air Lines
$34.15 /

+1.77 (+5.47%)

CEA China Eastern Airlines
$20.34 /

+1.54 (+8.19%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

AIRYY Air China
$0.00 /

+ (+0.00%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

AAL American Airlines
$18.59 /

+1.855 (+11.08%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

06/04/20 UBS
AstraZeneca price target raised to 7,300 GBp from 6,000 GBp at UBS
06/01/20 Piper Sandler
Aveo's tivozanib could launch in U.S. next year, says Piper Sandler
05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
JNJ Johnson & Johnson
$147.27 /

+0.61 (+0.42%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
MRK Merck
$82.26 /

+0.71 (+0.87%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
06/03/20 Alliance Global Partners
OpGen, NYS DOH collaboration extension 'highly positive,' says Alliance Global
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
MRNA Moderna
$58.16 /

-2.44 (-4.03%)

06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
PFE Pfizer
$35.97 /

-0.035 (-0.10%)

06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
06/01/20 Barclays
Pfizer price target lowered to $35 from $37 at Barclays
05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
INO Inovio
$11.96 /

+0.09 (+0.76%)

06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/01/20 Piper Sandler
Context 'may be necessary' for Inovio's INO-5401 GBM update, says Piper Sandler
05/21/20 Benchmark
Inovio initiated with a Buy at Benchmark
05/20/20 Roth Capital
Most of Inovio COVID-19 vaccine data 'over two months old,' says Roth Capital
NVAX Novavax
$46.22 /

+1.54 (+3.45%)

06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
AIRYY Air China
$0.00 /

+ (+0.00%)

03/18/20 Jefferies
Jefferies downgrades four China airlines on 'U-shaped' pandemic recovery
03/18/20 Jefferies
Air China downgraded to Underperform from Buy at Jefferies
03/09/20 Daiwa
Air China upgraded to Buy from Outperform at Daiwa
10/14/19 Goldman Sachs
Goldman upgrades China Southern to Buy on slower supply growth
CEA China Eastern Airlines
$20.34 /

+1.54 (+8.19%)

03/18/20 Jefferies
China Eastern Airlines downgraded to Hold from Buy at Jefferies
12/20/19 Daiwa
China Eastern Airlines upgraded to Buy from Outperform at Daiwa
ZNH China Southern Airlines
$25.21 /

+2.57 (+11.35%)

04/27/20 UBS
China Southern Airlines upgraded to Buy from Neutral at UBS
04/21/20 Credit Suisse
China Southern Airlines upgraded to Outperform from Neutral at Credit Suisse
03/18/20 Jefferies
China Southern Airlines downgraded to Hold from Buy at Jefferies
AAL American Airlines
$18.59 /

+1.855 (+11.08%)

06/05/20 Credit Suisse
American stock reaction to demand commentary 'confounding,' says Credit Suisse
06/05/20
Fly Intel: Top five analyst downgrades
06/05/20 Raymond James
American Airlines downgraded to Underperform from Market Perform at Raymond James
06/05/20 Raymond James
American downgraded to Underperform from Market Perform at Raymond James
DAL Delta Air Lines
$34.15 /

+1.77 (+5.47%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Delta Air Lines downgraded to Equal Weight from Overweight at Barclays
04/23/20 Raymond James
Delta Air Lines price target lowered to $36 from $40 at Raymond James
UAL United Airlines
$42.41 /

+3.33 (+8.52%)

05/26/20 Citi
Lufthansa bailout 'marginally positive' for United Airlines,says Citi
05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
SNAP Snap
$20.32 /

+1.065 (+5.53%)

06/01/20 Deutsche Bank
Snap price target raised to $24 from $18 at Deutsche Bank
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Citi
Snap downgraded to Sell from Neutral at Citi
04/27/20 JMP Securities
Facebook Q1 should benefit from same headwinds as Snap, says JMP Securities
FB Facebook
$230.64 /

+4.38 (+1.94%)

05/29/20 Baird
Twitter, Facebook pullbacks would likely be buying opportunities, says Baird
05/29/20 JPMorgan
Trump order may put 'overhang' on big tech in coming months, says JPMorgan
05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/27/20 Citi
Facebook price target raised to $275 from $245 at Citi
GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

06/02/20 Wells Fargo
Microsoft price target raised to $250 from $205 at Wells Fargo
05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/12/20 Citi
Alphabet price target raised to $1,600 from $1,400 at Citi
GOOGL Alphabet Class A
$1,440.74 /

+26.62 (+1.88%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

06/05/20 Credit Suisse
Apple price target raised to $295 from $260 at Credit Suisse
06/04/20 JPMorgan
'Way too early' for investors to write off Apple TV+, says JPMorgan
06/03/20 Bernstein
Apple could offer less expensive, easier to use Watch, says Bernstein
06/03/20 Morgan Stanley
Apple price target raised to $340 from $326 at Morgan Stanley
AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

06/05/20 DA Davidson
MongoDB price target raised to $215 from $105 at DA Davidson
06/05/20 SunTrust
eBay price target raised to $50 from $40 at SunTrust
06/05/20 RBC Capital
Slack Technologies price target raised to $38 from $28 at RBC Capital
06/05/20 JMP Securities
Domo price target raised to $35 from $22 at JMP Securities
UAL United Airlines
$42.41 /

+3.33 (+8.52%)

SNAP Snap
$20.32 /

+1.065 (+5.53%)

PFE Pfizer
$35.97 /

-0.035 (-0.10%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MRK Merck
$82.26 /

+0.71 (+0.87%)

JNJ Johnson & Johnson
$147.27 /

+0.61 (+0.42%)

INO Inovio
$11.96 /

+0.09 (+0.76%)

GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

DAL Delta Air Lines
$34.15 /

+1.77 (+5.47%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

AAL American Airlines
$18.59 /

+1.855 (+11.08%)

ZNH China Southern Airlines
$25.21 /

+2.57 (+11.35%)

UAL United Airlines
$42.41 /

+3.33 (+8.52%)

SNAP Snap
$20.32 /

+1.065 (+5.53%)

PFE Pfizer
$35.97 /

-0.035 (-0.10%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MRK Merck
$82.26 /

+0.71 (+0.87%)

JNJ Johnson & Johnson
$147.27 /

+0.61 (+0.42%)

INO Inovio
$11.96 /

+0.09 (+0.76%)

GOOGL Alphabet Class A
$1,440.74 /

+26.62 (+1.88%)

GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

DAL Delta Air Lines
$34.15 /

+1.77 (+5.47%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

AIRYY Air China
$0.00 /

+ (+0.00%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

AAL American Airlines
$18.59 /

+1.855 (+11.08%)

ZNH China Southern Airlines
$25.21 /

+2.57 (+11.35%)

SNAP Snap
$20.32 /

+1.065 (+5.53%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MRK Merck
$82.26 /

+0.71 (+0.87%)

JNJ Johnson & Johnson
$147.27 /

+0.61 (+0.42%)

INO Inovio
$11.96 /

+0.09 (+0.76%)

GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

DAL Delta Air Lines
$34.15 /

+1.77 (+5.47%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

AAL American Airlines
$18.59 /

+1.855 (+11.08%)

UAL United Airlines
$42.41 /

+3.33 (+8.52%)

SNAP Snap
$20.32 /

+1.065 (+5.53%)

PFE Pfizer
$35.97 /

-0.035 (-0.10%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MRK Merck
$82.26 /

+0.71 (+0.87%)

JNJ Johnson & Johnson
$147.27 /

+0.61 (+0.42%)

INO Inovio
$11.96 /

+0.09 (+0.76%)

GOOGL Alphabet Class A
$1,440.74 /

+26.62 (+1.88%)

GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

DAL Delta Air Lines
$34.15 /

+1.77 (+5.47%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

AAL American Airlines
$18.59 /

+1.855 (+11.08%)

GOOGL Alphabet Class A
$1,440.74 /

+26.62 (+1.88%)

GOOG Alphabet
$1,436.75 /

+24.625 (+1.74%)

AMZN Amazon.com
$2,481.08 /

+20.67 (+0.84%)

AAPL Apple
$331.38 /

+9.09 (+2.82%)

Hot Stocks
Piedmont Lithium Ltd (ADR) trading halted, news pending  19:55
06/05/20
06/05
19:55
06/05/20
19:55
PLL

Piedmont Lithium

$8.36 /

-0.19 (-2.22%)

 
ShowHide Related Items >><<
PLL Piedmont Lithium
$8.36 /

-0.19 (-2.22%)

PLL Piedmont Lithium
$8.36 /

-0.19 (-2.22%)

05/27/20 Roth Capital
Piedmont Lithium price target lowered to $20 from $28 at Roth Capital
Periodicals
Ascena Retail said to consider bankruptcy filing, Bloomberg reports  18:58
06/05/20
06/05
18:58
06/05/20
18:58
ASNA

Ascena Retail

$2.76 /

+0.84 (+43.75%)

 
ShowHide Related Items >><<
ASNA Ascena Retail
$2.76 /

+0.84 (+43.75%)

ASNA Ascena Retail
$2.76 /

+0.84 (+43.75%)

06/11/19 B. Riley FBR
Ascena Retail price target lowered to $1 from $2 at B. Riley FBR
ASNA Ascena Retail
$2.76 /

+0.84 (+43.75%)

ASNA Ascena Retail
$2.76 /

+0.84 (+43.75%)

Hot Stocks
Fang Holdings announces ADS ratio change » 18:02
06/05/20
06/05
18:02
06/05/20
18:02
SFUN

Fang Holdings

$1.33 /

+0.1 (+8.13%)

Fang Holdings announced…

Fang Holdings announced that the ratio of American depositary shares representing its Class A ordinary shares is being amended from one ADS representing one Class A ordinary share to one ADS representing ten Class A ordinary shares, mainly in preparation for the pending spin-off of its internet businesses. There will be no change to Fang's Class A ordinary shares. Furthermore, no physical action by ADS holders will be required to effect the ratio change, as the change will be effected on the books of the depositary. The effect of the ratio change on the ADS trading price on New York Stock Exchange is expected to take place at the open of business on June 19 (U.S. Eastern Time). Any fractional ADSs will be sold and the net proceeds from the sale of fractional ADSs will be distributed to the holders entitled thereto. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although Fang can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than ten times the ADS price before the change.

ShowHide Related Items >><<
SFUN Fang Holdings
$1.33 /

+0.1 (+8.13%)

Hot Stocks
Facebook CEO pledges to review platform's content policies » 18:01
06/05/20
06/05
18:01
06/05/20
18:01
FB

Facebook

$230.64 /

+4.38 (+1.94%)

Facebook CEO Mark…

Facebook CEO Mark Zuckerberg said in a post on his company's platform that, in response to criticism from employees over the company's decision to leave up controversial posts from U.S. President Donald Trump, the social media giant is going to review its policies allowing discussion and threats of state use of force to see if there are any amendments the company should adopt. "There are two specific situations under this policy that we're going to review," Zuckerbereg said. "The first is around instances of excessive use of police or state force. Given the sensitive history in the US, this deserves special consideration. The second case is around when a country has ongoing civil unrest or violent conflicts. We already have precedents for imposing greater restrictions during emergencies and when countries are in ongoing states of conflict, so there may be additional policies or integrity measures to consider around discussion or threats of state use of force when a country is in this state." The CEO added that Facebook will review policies around voter suppresion, as well as potential options for handling violating or partially-violating content aside from the "binary leave-it-up or take-it-down decisions." Zuckerberg also said he will work to establish a clearer and more transparent decision-making proces, as well as review whether the company needs to change anything structurally "to make sure the right groups and voices are at the table." Zuckerberg also said Facebook has started a workstream for building products to advance racial justice and that Facebook is building a voter hub to "double down" on previous "get-out-the-vote efforts." "To members of our Black community: I stand with you. Your lives matter. Black lives matter," he added. Reference Link

ShowHide Related Items >><<
FB Facebook
$230.64 /

+4.38 (+1.94%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

05/29/20 Baird
Twitter, Facebook pullbacks would likely be buying opportunities, says Baird
05/29/20 JPMorgan
Trump order may put 'overhang' on big tech in coming months, says JPMorgan
05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/27/20 Citi
Facebook price target raised to $275 from $245 at Citi
FB Facebook
$230.64 /

+4.38 (+1.94%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

Syndicate
Pretium Resources files $600M mixed securities shelf  17:51
06/05/20
06/05
17:51
06/05/20
17:51
PVG

Pretium Resources

$8.37 /

-0.225 (-2.62%)

 
ShowHide Related Items >><<
PVG Pretium Resources
$8.37 /

-0.225 (-2.62%)

PVG Pretium Resources
$8.37 /

-0.225 (-2.62%)

05/04/20 BMO Capital
Pretium Resources price target raised to C$13 from C$12 at BMO Capital
03/13/20 Roth Capital
Pretium Resources upgraded to Buy from Neutral at Roth Capital
02/13/20
Fly Intel: Top five analyst downgrades
02/13/20 Canaccord
Canaccord downgrades Pretium Resources, negative outlook cited
PVG Pretium Resources
$8.37 /

-0.225 (-2.62%)

PVG Pretium Resources
$8.37 /

-0.225 (-2.62%)

Hot Stocks
General Electric awarded $180.6M Navy procurement contract » 17:37
06/05/20
06/05
17:37
06/05/20
17:37
GE

General Electric

$7.88 /

+0.135 (+1.74%)

General Electric was…

General Electric was awarded a $180.6M firm-fixed-price, indefinite-delivery/indefinite-quantity contract. This contract procures commercial depot level services for the repair and overhaul of T700-GE-401/401C turbo shaft engines, cold section modules and power turbine modules for the Navy H-60 Seahawk helicopter as well as the Marine Corps H-1 Cobra and Bell UH-1 Huey aircraft. Work will be performed in Wingsfield, Kansas and is expected to be complete by June 2025. No funds will be obligated at the time of award. Funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to 10 U.S. Code 2304. The Naval Air Warfare Center Aircraft Division is the contracting activity.

ShowHide Related Items >><<
GE General Electric
$7.88 /

+0.135 (+1.74%)

GE General Electric
$7.88 /

+0.135 (+1.74%)

06/05/20 Citi
Recovery at GE Healthcare is underway, says Citi
06/03/20 JPMorgan
Raytheon presentation indicates GE estimates not 'reset,' says JPMorgan
04/30/20 William Blair
GE business remains solid despite big 2020 challenges, says William Blair
04/30/20 Credit Suisse
General Electric price target lowered to $8 from $9 at Credit Suisse
GE General Electric
$7.88 /

+0.135 (+1.74%)

GE General Electric
$7.88 /

+0.135 (+1.74%)

GE General Electric
$7.88 /

+0.135 (+1.74%)

GE General Electric
$7.88 /

+0.135 (+1.74%)

Syndicate
Bicycle Therapeutics files $250M mixed securities shelf  17:29
06/05/20
06/05
17:29
06/05/20
17:29
BCYC

Bicycle Therapeutics

$17.20 /

+0.2 (+1.18%)

 
ShowHide Related Items >><<
BCYC Bicycle Therapeutics
$17.20 /

+0.2 (+1.18%)

BCYC Bicycle Therapeutics
$17.20 /

+0.2 (+1.18%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BCYC Bicycle Therapeutics
$17.20 /

+0.2 (+1.18%)

BCYC Bicycle Therapeutics
$17.20 /

+0.2 (+1.18%)

Syndicate
Digimarc files $100M mixed securities shelf  17:27
06/05/20
06/05
17:27
06/05/20
17:27
DMRC

Digimarc

$17.82 /

-0.22 (-1.22%)

 
ShowHide Related Items >><<
DMRC Digimarc
$17.82 /

-0.22 (-1.22%)

DMRC Digimarc
$17.82 /

-0.22 (-1.22%)

02/27/20 Craig-Hallum
Digimarc downgraded to Hold at Craig-Hallum after mixed quarter, soft bookings
02/27/20 Craig-Hallum
Digimarc downgraded to Hold from Buy at Craig-Hallum
09/27/19 Northland
Digimarc solution being tested by P&G, other CPG companies, says Northland
09/12/19 Northland
Digimarc initiated with an Outperform at Northland
DMRC Digimarc
$17.82 /

-0.22 (-1.22%)

Syndicate
Core-Mark files automatic mixed securities shelf  17:27
06/05/20
06/05
17:27
06/05/20
17:27
CORE

Core-Mark

$28.31 /

+0.275 (+0.98%)

 
ShowHide Related Items >><<
CORE Core-Mark
$28.31 /

+0.275 (+0.98%)

CORE Core-Mark
$28.31 /

+0.275 (+0.98%)

02/11/20
Fly Intel: Top five analyst upgrades
02/11/20 Jefferies
Jefferies upgrades Core-Mark to Buy after 30% pullback since earnings
02/10/20 Jefferies
Core-Mark upgraded to Buy from Hold at Jefferies
11/08/19 Raymond James
Core-Mark price target lowered to $31 from $42 at Raymond James
CORE Core-Mark
$28.31 /

+0.275 (+0.98%)

Syndicate
Jaguar Health files to sell 9.15M shares of common stock for holders  17:25
06/05/20
06/05
17:25
06/05/20
17:25
JAGX

Jaguar Health

$0.47 /

+0.0295 (+6.70%)

 
ShowHide Related Items >><<
JAGX Jaguar Health
$0.47 /

+0.0295 (+6.70%)

JAGX Jaguar Health
$0.47 /

+0.0295 (+6.70%)

11/18/19 H.C. Wainwright
Jaguar Health price target lowered to $3 from $10 at H.C. Wainwright
09/12/19 Ladenburg
Jaguar Health initiated with a Buy at Ladenburg
JAGX Jaguar Health
$0.47 /

+0.0295 (+6.70%)

Syndicate
NGM Biopharmaceuticals files $400M mixed securities shelf  17:24
06/05/20
06/05
17:24
06/05/20
17:24
NGM

NGM Biopharmaceuticals

$20.66 /

+1.17 (+6.00%)

 
ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.66 /

+1.17 (+6.00%)

NGM NGM Biopharmaceuticals
$20.66 /

+1.17 (+6.00%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
NGM NGM Biopharmaceuticals
$20.66 /

+1.17 (+6.00%)

NGM NGM Biopharmaceuticals
$20.66 /

+1.17 (+6.00%)

NGM NGM Biopharmaceuticals
$20.66 /

+1.17 (+6.00%)

Hot Stocks
Frank's International's Mosing sells 236,166 common shares » 17:18
06/05/20
06/05
17:18
06/05/20
17:18
FI

Frank's International

$2.77 /

+0.49 (+21.49%)

In a regulatory filing,…

In a regulatory filing, Frank's International director D. Keith Mosing disclosed the sale of 236,166 common shares of the company on June 3 at a price of $2.1608 per share.

ShowHide Related Items >><<
FI Frank's International
$2.77 /

+0.49 (+21.49%)

FI Frank's International
$2.77 /

+0.49 (+21.49%)

07/02/19 Tudor Pickering
Frank's International upgraded to Buy from Hold at Tudor Pickering
FI Frank's International
$2.77 /

+0.49 (+21.49%)

Syndicate
Castor Maritime files to sell $5.75M of common shares, warrants » 17:17
06/05/20
06/05
17:17
06/05/20
17:17
CTRM

Castor Maritime

$0.76 /

+0.0175 (+2.36%)

Maxim Group is acting as…

Maxim Group is acting as sole book running manager for the offering.

ShowHide Related Items >><<
CTRM Castor Maritime
$0.76 /

+0.0175 (+2.36%)

CTRM Castor Maritime
$0.76 /

+0.0175 (+2.36%)

Hot Stocks
SCWorx receives notification of deficiency from Nasdaq » 17:14
06/05/20
06/05
17:14
06/05/20
17:14
WORX

SCWorx

$5.78 /

+ (+0.00%)

SCWorx announced that on…

SCWorx announced that on June 1 and June 2, 2020, the Nasdaq Stock Market notified the company that it was not in compliance with the Nasdaq's rules for continued listing because the company has not yet filed its 10-K for the fiscal year ended December 31, 2019, as required by Nasdaq Rule 5250(c)(1). The Nasdaq notification requires the company to submit its plan to regain compliance, no later than July 3, 2020. In response to the Nasdaq notification, the company intends to file its 2019 10-K during the week ended June 12, 2020, but in any case, before the due date for submitting its compliance plan to Nasdaq, the effect of which will be that the company will have cured the deficiency specified in the notification.

ShowHide Related Items >><<
WORX SCWorx
$5.78 /

+ (+0.00%)

WORX SCWorx
$5.78 /

+ (+0.00%)

WORX SCWorx
$5.78 /

+ (+0.00%)

Syndicate
Alnylam files to sell 963.5K shares of common stock for holders  17:14
06/05/20
06/05
17:14
06/05/20
17:14
ALNY

Alnylam

$127.54 /

-4.08 (-3.10%)

 
ShowHide Related Items >><<
ALNY Alnylam
$127.54 /

-4.08 (-3.10%)

ALNY Alnylam
$127.54 /

-4.08 (-3.10%)

05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
05/07/20 Cantor Fitzgerald
Alnylam's fundamental launch trends look 'good,' says Cantor Fitzgerald
05/07/20 Barclays
Alnylam price target raised to $156 from $143 at Barclays
ALNY Alnylam
$127.54 /

-4.08 (-3.10%)

ALNY Alnylam
$127.54 /

-4.08 (-3.10%)

Hot Stocks
On Deck Capital receives noncompliance notice from NYSE » 17:14
06/05/20
06/05
17:14
06/05/20
17:14
ONDK

On Deck Capital

$0.97 /

+0.1124 (+13.18%)

OnDeck Capital announced…

OnDeck Capital announced that it received notice from the NYSE, that the company does not meet an NYSE continued listing standard that requires the company to maintain a minimum average closing price of $1.00 per share over a period of 30 consecutive trading days. The company notified the NYSE of its intent to cure the deficiency and return to compliance with the NYSE continued listing requirements and is evaluating options to do so. Under the NYSE's rules, the cure period traditionally extends for six months following receipt of the notification. However, the NYSE has extended the cure period relating to this listing standard to January 1, 2021, in recognition of unprecedented market declines resulting from COVID-19. The company can regain compliance if, by the end of the cure period, OnDeck common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the preceding 30 trading-day period. Alternatively, the company can also demonstrate an accelerated cure based on a $1.00 share price on both the last trading day of any calendar month within the cure period and the average share price of the 30-trading days preceding the end of that month. During the cure period, the company's common shares will continue to trade on the NYSE under the symbol (ONDK) but will have an added designation of to indicate the status of the shares as "below compliance" subject to compliance with other continued listing requirements.

ShowHide Related Items >><<
ONDK On Deck Capital
$0.97 /

+0.1124 (+13.18%)

ONDK On Deck Capital
$0.97 /

+0.1124 (+13.18%)

05/01/20 BTIG
On Deck Capital downgraded to Neutral from Buy at BTIG
04/30/20 Janney Montgomery Scott
On Deck Capital downgraded to Neutral from Buy at Janney Montgomery Scott
04/15/20 B. Riley FBR
B. Riley FBR downgrades On Deck Capital to Neutral, halves target to $3
04/15/20 B. Riley FBR
On Deck Capital downgraded to Neutral from Buy at B. Riley FBR
ONDK On Deck Capital
$0.97 /

+0.1124 (+13.18%)

ONDK On Deck Capital
$0.97 /

+0.1124 (+13.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.